G Superti-Furga
Overview
Explore the profile of G Superti-Furga including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
2215
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hadzijusufovic E, Albrecht-Schgoer K, Huber K, Hoermann G, Grebien F, Eisenwort G, et al.
Leukemia
. 2017 Aug;
31(11):2388-2397.
PMID: 28757617
The BCR/ABL1 inhibitor Nilotinib is increasingly used to treat patients with chronic myeloid leukemia (CML). Although otherwise well-tolerated, Nilotinib has been associated with the occurrence of progressive arterial occlusive disease...
2.
Byrgazov K, Kastner R, Gorna M, Hoermann G, Koenig M, Lucini C, et al.
Leukemia
. 2016 Aug;
31(1):237-240.
PMID: 27573554
No abstract available.
3.
Pathria G, Garg B, Borgdorff V, Garg K, Wagner C, Superti-Furga G, et al.
Cell Death Dis
. 2016 Mar;
7:e2135.
PMID: 26962685
MITF (microphthalmia-associated transcription factor) is a frequently amplified lineage-specific oncogene in human melanoma, whose role in intrinsic drug resistance has not been systematically investigated. Utilizing chemical inhibitors for major signaling...
4.
Peter B, Winter G, Blatt K, Bennett K, Stefanzl G, Rix U, et al.
Leukemia
. 2015 Sep;
30(2):464-72.
PMID: 26349526
Proteomic-based drug testing is an emerging approach to establish the clinical value and anti-neoplastic potential of multikinase inhibitors. The multikinase inhibitor midostaurin (PKC412) is a promising new agent used to...
5.
Fauster A, Rebsamen M, Huber K, Bigenzahn J, Stukalov A, Lardeau C, et al.
Cell Death Dis
. 2015 May;
6:e1767.
PMID: 25996294
Necroptosis is a form of regulated necrotic cell death mediated by receptor-interacting serine/threonine-protein kinase 1 (RIPK1) and RIPK3. Necroptotic cell death contributes to the pathophysiology of several disorders involving tissue...
6.
Licciardello M, Mullner M, Durnberger G, Kerzendorfer C, Boidol B, Trefzer C, et al.
Oncogene
. 2014 Sep;
34(29):3780-90.
PMID: 25263445
Breast cancer is genetically heterogeneous, and recent studies have underlined a prominent contribution of epigenetics to the development of this disease. To uncover new synthetic lethalities with known breast cancer...
7.
Borgdorff V, Rix U, Winter G, Gridling M, Muller A, Breitwieser F, et al.
Oncogene
. 2013 Jun;
33(19):2531-9.
PMID: 23728343
The microphthalmia-associated transcription factor (MITF) is indispensable for the viability of melanocytic cells, is an oncogene in melanoma and has a cell type-specific expression pattern. As the modulation of MITF...
8.
Rix U, Remsing Rix L, Terker A, Fernbach N, Hantschel O, Planyavsky M, et al.
Leukemia
. 2009 Nov;
24(1):44-50.
PMID: 19890374
Resistance to the BCR-ABL tyrosine kinase inhibitor imatinib poses a pressing challenge in treating chronic myeloid leukemia (CML). This resistance is often caused by point mutations in the ABL kinase...
9.
Sillaber C, Herrmann H, Bennett K, Rix U, Baumgartner C, Bohm A, et al.
Eur J Clin Invest
. 2009 Sep;
39(12):1098-109.
PMID: 19744184
Background: The multikinase inhibitor dasatinib exerts growth-inhibitory effects in patients with imatinib-resistant chronic myeloid leukaemia (CML). In first clinical trials, side effects of dasatinib, 140 mg daily, were reported to...
10.
Remsing Rix L, Rix U, Colinge J, Hantschel O, Bennett K, Stranzl T, et al.
Leukemia
. 2008 Nov;
23(3):477-85.
PMID: 19039322
The detailed molecular mechanism of action of second-generation BCR-ABL tyrosine kinase inhibitors, including perturbed targets and pathways, should contribute to rationalized therapy in chronic myeloid leukemia (CML) or in other...